Global X S&P Biotech ETF (ASX:CURE)
Australia · Delayed Price · Currency is AUD 64.58
+0.39 (0.61%)
Jun 1, 2026, 3:06 PM AEST
54.06% (1Y)
| Assets | 41.20M |
| Expense Ratio | 0.45% |
| PE Ratio | n/a |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +53.13% |
| Volume | 2,578 |
| Open | 64.19 |
| Previous Close | 64.19 |
| Day's Range | 64.00 - 64.79 |
| 52-Week Low | 41.33 |
| 52-Week High | 65.95 |
| Beta | 0.35 |
| Holdings | 10 |
| Inception Date | Nov 8, 2018 |
About CURE
The Global X S&P Biotech ETF (CURE) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the S&P Biotechnology Select Industry Index.
Asset Class Equity
Category Health Care
Region North America
Stock Exchange Australian Securities Exchange
Ticker Symbol CURE
Provider Global X
Index Tracked S&P Biotechnology Select Industry
Performance
CURE had a total return of 53.13% in the past year, including dividends. Since the fund's inception, the average annual return has been 6.85%.
Top Holdings
15.46% of assets| Name | Symbol | Weight |
|---|---|---|
| Travere Therapeutics, Inc. | TVTX | 1.85% |
| Revolution Medicines, Inc. | RVMD | 1.76% |
| TG Therapeutics, Inc. | TGTX | 1.60% |
| Alkermes plc | ALKS | 1.57% |
| Twist Bioscience Corporation | TWST | 1.57% |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1.56% |
| Beam Therapeutics Inc. | BEAM | 1.40% |
| Madrigal Pharmaceuticals, Inc. | MDGL | 1.40% |
| Cytokinetics, Incorporated | CYTK | 1.39% |
| Neurocrine Biosciences, Inc. | NBIX | 1.38% |